botensilimab/balstilimab

Actionable Insights Powered by AI

Agenus Announces Strategic Realignment: Focus on Core Programs, Significant Cost Reductions, and Layoffs

Agenus, strategic realignment, layoffs, cost reduction, botensilimab/balstilimab (BOT/BAL), cancer drug development